Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.67 |
| ▸ | ECE1 | P42892 | 10/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.60 |
| ▸ | IL1RN | P18510 | 2/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123123 | 0.93 | ERAP2 (0.76) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL31074338 | 0.92 | ERAP2 (0.67) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL31373854 | 0.91 | ECE1 (0.75) | ERAP2ECE1ACE | |
| SCHEMBL30958345 | 0.89 | ERAP2 (0.57) | ERAP2ECE1ACE | |
| SCHEMBL31042843 | 0.89 | ERAP2 (0.73) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL31720529 | 0.88 | ERAP2 (0.74) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL30734418 | 0.88 | ERAP2 (0.66) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL30311117 | 0.88 | ECE1 (0.72) | ERAP2ECE1ACE | |
| SCHEMBL29883632 | 0.88 | MMP2 (0.67) | ERAP2ECE1ACEIL1RNERAP1 | |
| SCHEMBL30788008 | 0.87 | ECE1 (0.66) | ERAP2ECE1ACEIL1RNERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | ERAP2 430/4885ECE1 503/4885ACE 1075/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | ERAP2 430/4885ECE1 503/4885ACE 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.